

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**Shanghai HeartCare Medical Technology
Corporation Limited**

上海心瑋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6609)

**GRANT OF AWARDS PURSUANT TO
2025 H SHARE INCENTIVE SCHEME**

This announcement is made by Shanghai HeartCare Medical Technology Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 17.06A, 17.06B and 17.06C of the Rules Governing the Listing of Securities (the “**Listing Rules**”) of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board announces that on September 21, 2026, the Company made a grant of 30,000 share awards (the “**Awards**”) to an employee (the “**Grantee**”) of the Group (the “**September 2026 Second Grant**”) under the 2025 H Share Incentive Scheme adopted by the Company on May 26, 2025, as amended from time to time (the “**2025 H Share Incentive Scheme**”).

Details of the September 2026 Second Grant are set out below:

Date of Grant:	September 21, 2026
Number of Grantee:	1 employee of the Group
Number of Awards granted:	30,000 Share awards, representing 30,000 H Shares, approximately 0.10% of the total issued H shares (“ H Share(s) ”) (excluding treasury shares) of the Company and 0.08% of the total issued share capital (excluding treasury shares) of the Company as of the date of this announcement

Issue Price of the Share Awards:	Nil
Closing price of the H Shares on the date of grant:	HK\$55.00 per H Share
Vesting period of the Share Awards:	The Awards comprise (i) 3,000 Share awards of one year awards and (ii) 27,000 Share awards of three year awards. The Awards will be assessed in succession across the four assessment years from 2026 to 2029. For the first two assessment years (i.e. 2026 to 2027), the relevant Awards shall vest on September 30 of the following year. For the latter two assessment years (i.e. 2028 to 2029), the relevant Awards shall vest on September 30 of the following year and March 31 of the year after that in such portion as set forth in the grant letter. The Company has the right to extend the vesting period to no later than March, 2031 based on the actual performance of the Grantee and the Group if the performance target are not met or are only partially met at the respective vesting date. Therefore the latest vesting date of Awards will be March 31, 2031.
Performance Targets of the Share Awards:	The September 2026 Second Grant is subject to individual performance targets, which requires the Grantee to achieve a “B” grading or above for all personal evaluations in each assessment year, as well as the achievement of certain financial, operational or market capitalization targets as determined by the Board. The Group financial performance target for the assessment year of 2026, 2027, 2028 and 2029 includes the increase in the Company’s revenue by 47%, 40%, 35% and 35% for each respective period as compared with the preceding assessment year. If the performance target is not met (or only partially met), the Company may extend the vesting period of unvested portions of the Awards to March 31, 2031.

Clawback Mechanism of the Share Awards:

The September 2026 Second Grant is subject to clawback at the sole and absolute discretion of the Board in accordance to the 2025 H Share Incentive Scheme. The awards granted may be clawback by the Company under the following circumstances:

- (i) when the Grantee has committed any act of fraud or dishonesty or serious misconduct in connection with their employment or engagement by any member of the Group;
- (ii) when the Grantee has engaged in any act or omission to perform any of his/her duties that has had or will have a material adverse effect on the reputation or interests of any member of the Group;
- (iii) when the Grantee has engaged in any act that has had or will have a material adverse effect on the reputation or interests of any member of the Group after they cease to be an “eligible participant” under the 2025 H Share Incentive Scheme; or
- (iv) there has been a material misstatement to the Company’s financial statement.

The Company has not made any arrangements to provide financial assistance to the Grantee to facilitate the purchase of Awards.

LISTING RULES IMPLICATIONS

To the best of the Directors’ knowledge, information and belief, having made all reasonable enquiries as (i) the Grantee is not a Director, chief executive or substantial shareholder of the Company, or their respective associates (as defined under the Listing Rules); (ii) the Grantee is not a participant with options and share awards granted and to be granted exceeding the 1% individual limit under Rule 17.03D(1) of the Listing Rules; (iii) the Grantee is not a related entity participant (as defined under the Listing Rules); and (iv) no financial assistance has been provided by the Group to the Grantee for the purchase of Shares under the 2025 H Share Incentive Scheme, the September 2026 Second Grant will not be subject to approval by the shareholders of the Company.

NUMBER OF SHARES AVAILABLE FOR FUTURE GRANT UNDER THE 2025 H SHARE INCENTIVE SCHEME

After having made the September 2026 Second Grant, the number of H Shares available for future grant under the 2025 H Share Incentive Scheme's limit is 2,865,700 H Shares, representing approximately 9.37% of the total issued H Shares (excluding treasury shares) and 7.37% of the total issued share capital (excluding treasury shares) of the Company as of the date of this announcement, respectively. In accordance with the terms of the 2025 H Share Incentive Scheme, no H Shares may be granted to any service providers of the Group.

By order of the Board
Shanghai HeartCare Medical Technology Corporation Limited
WANG Guohui
Chairman of the Board

Shanghai, September 21, 2026

As at the date of this announcement, the executive Directors are Mr. Wang Guohui, Ms. Zhang Kun and Mr. Wei Jiawei; the non-executive Directors are Mr. Chen Shaoxiong and Mr. Chen Gang; and the independent non-executive Directors are Mr. Guo Shaomu, Mr. Feng Xiangqian and Mr. Gong Ping.